Surgery for pancreatic cancer;Chirurgie des pankreaskarzinoms

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 12, 2008, Pages 1393-1403

  Welsch, T ^a   Buchler M W ^a   Schmidt, Jan ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Inst fur Physiologie Pathophysiol   (Germany)

Author keywords

Gastro entero pancreatic tumours; High volume centres; Pancreatic cancer; Surgery

Indexed keywords

ANASTOMOSIS; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; EVIDENCE BASED PRACTICE; HUMAN; METASTASIS; PALLIATIVE THERAPY; PANCREAS CANCER; PANCREAS FISTULA; PANCREAS SURGERY; PANCREATICODUODENECTOMY; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; REVIEW; SPLENECTOMY; SURGICAL TECHNIQUE; TREATMENT INDICATION; TUMOR GROWTH;

CARCINOMA, PANCREATIC DUCTAL; HUMANS; LYMPH NODE EXCISION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; SPLENECTOMY; SURVIVAL RATE;

EID: 58149462690     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027790     Document Type: Review

References (101)

1. RKI. Krebs in Deutschland. 2008; 6. Aufl
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96
3. Fischer L, Kleeff J, Esposito I et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008; 95: 627-635
4. Woo SM, Ryu JK, Lee SH et al. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma. Pancreas 2008; 36: 50-55
5. Welsch T, Kleeff J, Friess H. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med 2007; 7: 504-521
6. Howard TJ, Krug JE, Yu J et al. A margin-negative RO resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006; 10: 1338-1345; discussion 1345-1336
7. Wagner M, Redaelli C, Lietz M et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91: 586-594
8. Alexakis N, Halloran C, Raraty M et al. Current standards of surgery for pancreatic cancer. Br J Surg 2004; 91: 1410-1427
9. Esposito I, Kleeff J, Bergmann F et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008; 15: 1651-1660
10. Verbeke CS. Resection margins and R1 rates in pancreatic cancer - are we there yet? Histopathology 2007; 52: 787-796
11. Friess H, Kleeff J, Fischer L et al. Surgical standard therapy for cancer of the pancreas. Chirurg 2003; 74: 183-190
12. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003; 185: 476-480
13. Grenacher L, Klauss M, Dukic L et al. Diagnosis and staging of pancreatic carcinoma: MRI versus multislice-CT - a prospective study. Röntgenstr Fortschr 2004; 176: 1624-1633
14. Miura F, Takada T, Amano H et al. Diagnosis of pancreatic cancer. HPB 2006; 8: 337-342
15. Aslanian H, Salem R, Lee J et al. EUS diagnosis of vascular invasion in pancreatic cancer: surgical and histologic correlates. Am J Gastroenterol 2005; 100: 1381-1385
16. Bao PQ, Johnson JC, Lindsey EH et al. Endoscopic ultrasound and computed tomography predictors of pancreatic cancer resectability. J Gastrointest Surg 2008; 12: 10-16; discussion 16
17. Friess H, Kleeff J, Silva JC et al. The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J Am Coll Surg 1998; 186: 675-682
18. White R, Winston C, Gonen M et al. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg 2008; 206: 445-450
19. Allendorf JD, Lauerman M, Bill A et al. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J Gastrointest Surg 2008; 12: 91-100
20. Krempien R, Muenter MW, Harms W et al. Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma. HPB 2006; 8: 22-28
21. Kleeff J, Friess H, Buchler MW. Neoadjuvant therapy for pancreatic cancer. Br J Surg 2007; 94: 261-262
22. Stitzenberg KB, Watson JC, Roberts A et al. Survival after pancreatectomy with major arterial resection and reconstruction. Ann Surg Oncol 2008; 15: 1399-1406
23. Varadhachary GR, Tamm EP, Abbruzzese JL et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-1046
24. Sohn TA, Lillemoe KD, Cameron JL et al. Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome. Ann Surg 1999; 229: 393-400
25. Michalski CW, Kleeff J, Bachmann J et al. Second-look operation for unresectable pancreatic ductal adenocarcinoma at a high-volume center. Ann Surg Oncol 2008; 15: 186-192
26. Adler G, Seufferlein T, Bischoff SC et al. S3-Guidelines "Exocrine pancreatic cancer" 2007. Z Gastroenterol 2007; 45: 487-523
27. Sasson AR, Hoffman JP, Ross EA et al. En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg 2002; 6: 147-157; discussion 157-148
28. Shrikhande SV, Kleeff J, Reiser C et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 2007; 14: 118-127
29. Gleisner AL, Assumpcao L, Cameron JL et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer 2007; 110: 2484-2492
30. Yamada H, Hirano S, Tanaka E et al. Surgical treatment of liver metastases from pancreatic cancer. HPB 2006; 8: 85-88
31. Kleeff J, Reiser C, Hinz U et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 2007; 245: 566-572
32. Messick C, Hardacre JM, McGee MF et al. Early experience with intraoperative radiotherapy in patients with resected pancreatic adenocarcinoma. Am J Surg 2008; 195: 308-311; discussion 312
33. Gouma DJ. Stent versus surgery. HPB 2007; 9: 408-413
34. Moss AC, Morris E, Leyden J et al. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev 2007; 33: 213-221
35. Lillemoe KD, Cameron JL, Hardacre JM et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 1999; 230: 322-328; discussion 328-330
36. Koninger J, Wente MN, Muller-Stich BP et al. R2 resection in pancreatic cancer-does it make sense? Langenbecks Arch Surg 2008; Epub ahead of print: Feb 29
37. Traverso LW, Longmire Jr WP. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet 1978; 146: 959-962
38. Diener MK, Knaebel HP, Heukaufer C et al. A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma. Ann Surg 2007; 245: 187-200
39. Weitz J, Koch M, Kleeff J et al. Kausch-Whipple pancreaticoduodenectomy. Technique and results. Chirurg 2004; 75: 1113-1119
40. Wente MN, Shrikhande SV, Muller MW et al. Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis. Am J Surg 2007; 193: 171-183
41. Tani M, Terasawa H, Kawai M et al. Improvement of delayed gastric emptying in pylorus-preserving pancreaticoduodenectomy: results of a prospective, randomized, controlled trial. Ann Surg 2006; 243: 316-320
42. Kausch W. Das Karzinom der Papilla duodeni und seine radikale Entfernung. Beitr Klin Chir 1912; 78: 439
43. Whipple AO, Parsons WB, Mullins CR. Treatment of Carcinoma of the Ampulla of Vater. Ann Surg 1935; 102: 763-779
44. Reddy SK, Tyler DS, Pappas TN et al. Extended resection for pancreatic adenocarcinoma. Oncologist 2007; 12: 654-663
45. Karpoff HM, Klimstra DS, Brennan MF et al. Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 2001; 136: 44-47; discussion 48
46. Muller MW, Friess H, Kleeff J et al. Is there still a role for total pancreatectomy? Ann Surg 2007; 246: 966-974; discussion 974-965
47. Schmidt CM, Glant J, Winter JM et al. Total pancreatectomy (RO resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma. Surgery 2007; 142: 572-578; discussion 578-580
48. Fujino Y, Sakai T, Kuroda Y. Palliative pancreatectomy with postoperative gemcitabine for patients with advanced pancreatic cancer. J Gastroenterol 2008; 43: 233-238
49. Brentnall TA. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 2005; 6: 437-445
50. Balcom JHt, Rattner DW, Warshaw AL et al. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001; 136: 391-398
51. Kleeff J, Diener MK, Z'Graggen K et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg 2007; 245: 573-582
52. Knaebel HP, Diener MK, Wente MN et al. Systematic review and metaanalysis of technique for closure of the pancreatic remnant after distal pancreatectomy. Br J Surg 2005; 92: 539-546
53. Winter JM, Cameron JL, Campbell KA et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10: 1199-1210; discussion 1210-1191
54. Pawlik TM, Gleisner AL, Cameron JL et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007; 141: 610-618
55. Michalski CW, Kleeff J, Wente MN et al. Systematic review and metaanalysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 2007; 94: 265-273
56. Pedrazzoli S, DiCarlo V, Dionigi R et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228: 508-517
57. Al-Haddad M, Martin JK, Nguyen J et al. Vascular resection and reconstruction for pancreatic malignancy: a single center survival study. J Gastrointest Surg 2007; 11: 1168-1174
58. Siriwardana HP, Siriwardena AK. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 2006; 93: 662-673
59. Tseng JF, Raut CP, Lee JE et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004; 8: 935-949; discussion 949-950
60. Yekebas EF, Bogoevski D, Cataldegirmen G et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg 2008; 247: 300-309
61. Weitz J, Kienle P, Schmidt J et al. Portal vein resection for advanced pancreatic head cancer. J Am Coll Surg 2007; 204: 712-716
62. Gagandeep S, Artinyan A, Jabbour N et al. Extended pancreatectomy with resection of the celiac axis: the modified Appleby operation. Am J Surg 2006; 192: 330-335
63. Welsch T, Frommhold K, Hinz U et al. Persisting elevation of C-reactive protein after pancreatic resections can indicate developing inflammatory complications. Surgery 2008; 143: 20-28
64. Yekebas EF, Wolfram L, Cataldegirmen G et al. Postpancreatectomy hemorrhage: diagnosis and treatment: an analysis in 1669 consecutive pancreatic resections. Ann Surg 2007; 246: 269-280
65. Berberat PO, Ingold H, Gulbinas A et al. Fast track - different implications in pancreatic surgery. J Gastrointest Surg 2007; 11: 880-887
66. Buchler MW, Friess H. Evidence forward, drainage on retreat: still we ignore and drain!? Ann Surg 2006; 244: 8-9
67. Kawai M, Tani M, Terasawa H et al. Early removal of prophylactic drains reduces the risk of intra-abdominal infections in patients with pancreatic head resection: prospective study for 104 consecutive patients. Ann Surg 2006; 244: 1-7
68. Birkmeyer JD, Sun Y, Wong SL et al. Hospital volume and late survival after cancer surgery. Ann Surg 2007; 245: 777-783
69. Fong Y, Gonen M, Rubin D et al. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 2005; 242: 540-544; discussion 544-547
70. van Heek NT, Kuhlmann KF, Scholten RJ et al. Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. Ann Surg 2005; 242: 781-788, discussion 788-790
71. Weitz J, Koch M, Friess H et al. Impact of volume and specialization for cancer surgery. Dig Surg 2004; 21: 253-261
72. Liu JH, Zingmond DS, McGory ML et al. Disparities in the utilization of high-volume hospitals for complex surgery. Jama 2006; 296: 1973-1980
73. Crippa S, Dominguez I, Rodriguez JR et al. Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg 2008; 12: 783-794
74. Makary MA, Winter JM, Cameron JL et al. Pancreaticoduodenectomy in the very elderly. J Gastrointest Surg 2006; 10: 347-356
75. Schnelldorfer T, Ware AL, Sarr MG et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008; 247: 456-462
76. Garcea G, Dennison AR, Pattenden CJ et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. Jop 2008; 9: 99-132
77. Raut CP, Tseng JF, Sun CC et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246: 52-60
78. Butturini G, Stocken DD, Wente MN et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008; 143: 75-83; discussion 83
79. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210
80. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 2007; 297: 267-277
81. Sultana A, Smith CT, Cunningham D et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607-2615
82. Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: a review. Cancer 2008; 112: 243-249
83. Knaebel HP, Marten A, Schmidt J et al. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma - CapRI: study protocol (ISRCTN62866759). BMC Cancer 2005; 5: 37
84. Sobin KL, Wittekind C. TNM Classification of Malignant Tumours. New Jersey: John Wiley & Sons, 2002; 6th ed
85. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721-731; discussion 731-723
86. Richter A, Niedergethmann M, Sturm JW et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003; 27: 324-329
87. Burris 3 rd HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
88. Conroy T, Paillot B, Francois E et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer - a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23: 1228-1236
89. Koeppler H, Dum M, Grundheber M et al. Palliative treatment of advanced pancreatic carcinoma in community-based oncology group practices. J Support Oncol 2004; 2: 159-163
90. Prost P, Ychou M, Azria D. Gemcitabine and pancreatic cancer. Bull Cancer 2002; 89 Spec No: S91-S95
91. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438
92. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516
93. Goldstein D, Carroll S, Apte M et al. Modern management of pancreatic carcinoma. Intern Med J 2004; 34: 475-481
94. Ueno H, Okusaka T, Ikeda M et al. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005; 68: 171-178
95. Van Cutsem E, Aerts R, Haustermans K et al. Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 2004; 16: 265-274
96. Nakao A, Takeda S, Inoue S et al. Indications and techniques of extended resection for pancreatic cancer. World J Surg 2006; 30: 976-982; discussion 983-974
97. Hirano S, Kondo S, Hara T et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results. Ann Surg 2007; 246: 46-51
98. Kondo S, Katoh H, Hirano S et al. Results of radical distal pancreatectomy with en bloc resection of the celiac artery for locally advanced cancer of the pancreatic body. Langenbecks Arch Surg 2003; 388: 101-106
99. Wente MN, Bassi C, Dervenis C et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2007; 142: 761-768
100. Bassi C, Dervenis C, Butturini G et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138: 8-13
101. Wente MN, Veit JA, Bassi C et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 2007; 142: 20-25